Chiesi was Protalix BioTherapeutics’s largest product and service line in fiscal 2025, bringing in $22.51M of $51.80M (43%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Chiesi | $29.33M | $22.51M |
| Pfizer | $12.62M | $18.23M |
| Fiocruz | $11.03M | $11.06M |
| Total | $52.98M | $51.80M |
Protalix BioTherapeutics brought in $51.80M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 2.2% from $52.98M in fiscal 2024. Chiesi was the largest at $22.51M (43.5%), ahead of Pfizer at $18.23M (35.2%) and Fiocruz at $11.06M (21.4%).
Compared with fiscal 2024, Pfizer grew fastest, up 44.5% to $18.23M, while Chiesi fell the most, down 23.3% to $22.51M.
Goods was Protalix BioTherapeutics’s largest product and service line in fiscal 2025, bringing in $22.51M of $23.46M (96%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License & Rd Services | $22.35M | $25.08M | $418.00K | $942.00K | |||||||||||
| Goods | $12.40M | $17.50M | $29.33M | $22.51M | |||||||||||
| Total | $34.75M | $42.57M | $29.75M | $23.46M |
Protalix BioTherapeutics brought in $23.46M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $51.80M it reports by product and service, so these lines do not cover all of its revenue. Goods was the largest at $22.51M (96.0%), ahead of License & Rd Services at $942.00K (4.0%).
Compared with fiscal 2024, License & Rd Services grew 125.4% to $942.00K, while Goods fell 23.3% to $22.51M.
Pfizer was Protalix BioTherapeutics’s largest region in fiscal 2017, bringing in $12.18M of $19.24M (63%).
| Geography | FY 2015 | FY 2017 |
|---|---|---|
| Pfizer | — | $12.18M |
| Brazil | $4.36M | $7.06M |
| Total | $4.36M | $19.24M |
Protalix BioTherapeutics brought in $19.24M from its two regions in fiscal 2017, the year ended December 31, 2017. Protalix BioTherapeutics regrouped these regions after fiscal 2015, so the total does not compare directly with that year's $4.36M. Pfizer was the largest at $12.18M (63.3%), ahead of Brazil at $7.06M (36.7%).
Protalix BioTherapeutics began breaking out Pfizer in fiscal 2017, when it brought in $12.18M.
Protalix BioTherapeutics (PLX) reports its revenue by product and service and by geography. In fiscal 2025, Chiesi was its largest product and service line, bringing in $22.51M (43.5% of the total), followed by Pfizer at $18.23M (35.2%).
Chiesi was Protalix BioTherapeutics' largest product and service line in fiscal 2025, bringing in $22.51M, or 43.5% of the $51.80M total across its three product and service lines.
Pfizer was Protalix BioTherapeutics' largest region in fiscal 2017, bringing in $12.18M, or 63.3% of the $19.24M total across its two regions.
Among Protalix BioTherapeutics' product and service lines that make up at least 2% of revenue, Pfizer grew fastest in fiscal 2025, up 44.5% from $12.62M to $18.23M.
Every figure comes from Protalix BioTherapeutics' annual financial filings, as reported. Each line keeps the name Protalix BioTherapeutics gives it, and years follow its fiscal calendar.
Protalix BioTherapeutics' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.